The Role of Glycosphingolipids in Diabetic Retinopathy
The Role of Glycosphingolipids in Diabetic Retinopathy
批准号:
7732069
负责人:
MARK KESTER
金额:
$38.61万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-08-01 至 2012-07-31
关键词:
ApoptosisBiochemicalBlindnessCell Culture TechniquesCell SurvivalCeramide glucosyltransferaseCeramidesClinicalComplications of Diabetes MellitusDataDiabetes MellitusDiabetic RetinopathyDiseaseEnzymesFunctional disorderFundingGlucosylceramidesGlycosphingolipidsGrantHyperglycemiaImpairmentIn VitroInflammationInflammatoryInsulin ReceptorInsulin-Dependent Diabetes MellitusInterventionLeadLipidsMass Spectrum AnalysisMeasuresMediatingMembraneMembrane MicrodomainsMetabolic stressMetabolismModelingMolecularNeuronsNeuropathyPatientsPharmaceutical PreparationsProductionProteinsPublishingRattusReceptor SignalingRegulationRetinaRetinalRoleSecond Messenger SystemsSignal TransductionSphingolipidsStreptozocinStressTherapeuticVascular PermeabilitiesVisionWorkbaseclinically relevantcytokinediabeticdiabetic ratimprovedin vivoinnovationinsightinsulin sensitivityinsulin signalinglipid metabolismmouse modelneuron apoptosisneuron lossnovelpreventpublic health relevanceretinal neuronsecond messengertherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Diabetic retinopathy is a debilitating complication of diabetes and a leading cause of vision loss; however the fundamental mechanisms contributing to vision loss remain undefined. In our previously funded R03 grant, we hypothesized that altered sphingolipid metabolism contributes to diabetic complications including neuronal apoptosis within the retina. We have now published that dysfunctional glycosphingolipid metabolism may contribute to metabolic stress in diabetes and therapeutic strategies to restore normal sphingolipid metabolism may be a viable approach for treatment of diabetic retinopathy. Specifically, our published and preliminary data demonstrate that glucosylceramide accumulates within diabetic retinas in vivo and that inhibition of glucosylceramide synthase improves insulin sensitivity under hyperglycemic conditions and diminishes inflammatory cytokine-induced retinal neuronal cell death. In the present proposal, we extend these observations to more mechanistic studies. We now hypothesize that hyperglycemia and/or inflammation directly regulate glucosylceramide synthase activity, resulting in accumulation of glucosylceramides. We also hypothesize that pharmacologically targeting glucosylceramide synthase may be therapeutic for diabetic retinopathy. PUBLIC HEALTH RELEVANCE: The underlying cause of diabetic retinopathy is still unknown. We have employed lipidomics, a sophisticated mass spectroscopy strategy, to quantify the mass of lipid metabolites within the diabetic retina. Preliminary and published data have identified dysfunctional glycosphingolipid metabolism in models of Type 1 diabetes. The clinical relevance of our studies is that these lipidomic studies have identified glucosylceramide synthase as a "drugable" target for diabetic complications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ceramide Nanoliposomes in Combination with Focused Ultrasound for Treating Breast Cancer
-
批准号:9750255
-
项目类别:
-
资助金额:$18.32万
-
财政年份:2018
-
负责人:MARK KESTER
-
依托单位:
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer
-
批准号:10206045
-
项目类别:
-
资助金额:$55.31万
-
财政年份:2017
-
负责人:MARK KESTER
-
依托单位:
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer
-
批准号:9403358
-
项目类别:
-
资助金额:$53.12万
-
财政年份:2017
-
负责人:MARK KESTER
-
依托单位:
Novel Nanoparticle Therapy for Pancreatic Cancer
-
批准号:9020214
-
项目类别:
-
资助金额:$31.32万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Clinical Trial of Ceramide nanoLiposomes in AML
-
批准号:10160825
-
项目类别:
-
资助金额:$57.19万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Biostatistics Core
-
批准号:8589114
-
项目类别:
-
资助金额:$2.3万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Administrative Core
-
批准号:8589115
-
项目类别:
-
资助金额:$8.56万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Novel Nanoparticle Therapy for Pancreatic Cancer
-
批准号:8827284
-
项目类别:
-
资助金额:$31.32万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Targeting Ceramide Metabolism in AML
-
批准号:8554594
-
项目类别:
-
资助金额:$30.57万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Novel Nanoparticle Therapy for Pancreatic Cancer
-
批准号:8638905
-
项目类别:
-
资助金额:$30.39万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Targeted Sphingolipid Metabolism for Treatment of AML
-
批准号:10160824
-
项目类别:
-
资助金额:$199.55万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Novel Nanoparticle Therapy for Pancreatic Cancer
-
批准号:8435991
-
项目类别:
-
资助金额:$31.33万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Targeted Sphingolipid Metabolism for Treatment of AML
-
批准号:8552151
-
项目类别:
-
资助金额:$198.9万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Targeting Acid Ceramidase in AML
-
批准号:8554595
-
项目类别:
-
资助金额:$32.75万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Targeted Sphingolipid Metabolism for Treatment of AML
-
批准号:8732613
-
项目类别:
-
资助金额:$192.93万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Novel Nanoparticle Therapy for Pancreatic Cancer
-
批准号:9248264
-
项目类别:
-
资助金额:$31.31万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Targeting Sphingosine Kinase in AML
-
批准号:8554596
-
项目类别:
-
资助金额:$22.07万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
The Role of Glycosphingolipids in Diabetic Retinopathy
-
批准号:7903885
-
项目类别:
-
资助金额:$38.22万
-
财政年份:2009
-
负责人:MARK KESTER
-
依托单位:
The Role of Glycosphingolipids in Diabetic Retinopathy
-
批准号:8106211
-
项目类别:
-
资助金额:$36.68万
-
财政年份:2009
-
负责人:MARK KESTER
-
依托单位:
PKC zeta as a Target for Ceramide
-
批准号:7148916
-
项目类别:
-
资助金额:$36.51万
-
财政年份:2006
-
负责人:MARK KESTER
-
依托单位:
海外基金